Atrial fibrillation with rapid ventricular response (heart rate \> 110 bpm) or ventricular arrhythmia (frequent PVCs, ventricular tachycardia).
Acute myocardial infarction within 12 weeks of patient study registration.
Known pulmonary embolism.
Known or suspected lung cancer.
Known neuromuscular disease, stroke with residual hemiparesis, or untreated Parkinsonism
Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception (i.e., oral contraceptives, intrauterine devices, diaphragm, or sub dermal implants).
Inability to understand instructions.
Participation in another investigational drug clinical trial within 30 days of patient study registration.
Clareo Health | COPD Aerosol Study Comparing the Efficacy of Nebulizers Versus Dry Powder Inhalers
